Biomarker Database Registry for Photodynamic Therapy

Status Completed

Clinical Trial Summary

The purpose of this research is to obtain a blood sample from patients with actinic keratoses undergoing routine Photodynamic Therapy, in order to measure biomarkers that are relevant to VitD and 5FU metabolism and might be predictive of PDT outcome. The biomarkers to be examined include serum VitD levels at the time of PDT, and the presence/absence of gene alleles that correlate with expression of several proteins involved in VitD and 5FU metabolism. The presence of these biomarkers will be correlated to the improvement in AK lesion counts at the patient's routine follow-up visit 3 months after PDT treatment.

Clinical Trial Description

Patients who have been scheduled to receive PDT in our noninvasive cutaneous oncology clinics will be given written information prior to their visit, including a copy of the Informed Consent (IC) that describes the purpose of the study. If the patient indicates that he/she is interested, the physician or study nurse will review the IC with the patient on the day of PDT and answer all questions. After the patient signs the IC, the patient will have their blood drawn by a caregiver who has completed PTS Phlebotomy Training. DNA samples will be stored in a locked minus 80 degree ultrafreezer, in Dr. Maytin's laboratory (room ND4-25A in the Lerner Research Institute). The samples will be maintained for up to 10 years. Blood sample tubes and data sheets in the laboratory will be labeled with a code consisting of the first 5 digits of the patient's 8-digit MRN along with the date that the phlebotomy was performed (i.e. the date of the blood draw). This should ensure anonymity of the data while preventing mistakes when linking the laboratory results to the correct patient. Study personnel with password-protected access to the database registry will use the code to unequivocally identify the subject's file within the Oracle database and thereby enter the subject's laboratory results into the proper data field. The Informed Consent document informs the subject that he/she can withdraw permission for use of their samples at any time, and explains how to do this by contacting the Principal Investigator (PI) in writing. Information will not be disclosed to third party outside of Cleveland Clinic for research purposes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03319251
Study type	Observational [Patient Registry]
Source	The Cleveland Clinic
Contact
Status	Completed
Phase
Start date	October 6, 2017
Completion date	October 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03013647` - Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization	N/A
Completed	`NCT02674048` - Metvix Daylight PDT in Actinic Keratosis
Completed	`NCT02239679` - Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy	Phase 2
Completed	`NCT02421471` - PMS to Evaluate the Safety and Efficacy of Picato® Gel
Completed	`NCT01686152` - Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis	Phase 3
Completed	`NCT01444989` - Development and Validation of a Quality of Life Instrument for Actinic Keratosis	N/A
Completed	`NCT01449513` - PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy	Phase 1
Terminated	`NCT01525329` - Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease	Phase 3
Terminated	`NCT01203878` - Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy	Phase 4
Completed	`NCT00989313` - A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study	Phase 3
Completed	`NCT00306800` - Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp	Phase 3
Completed	`NCT00375739` - Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses	Phase 2
Completed	`NCT03285490` - A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)	Phase 3
Completed	`NCT02866695` - Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients	Phase 4
Completed	`NCT02952898` - Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses	Phase 3
Completed	`NCT02984072` - Menthol for PDT Pain Relief	Phase 4
Recruiting	`NCT03684772` - Topical Ionic Contra-Viral Therapy in Actinic Keratosis	Phase 2
Completed	`NCT02878382` - Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT	N/A
Completed	`NCT02938715` - Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil	N/A
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A